Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CANO Cano Health		$3.81	$1.74 ▼ $190.00	$12.39M	0.05	423,785 shs	159,142 shs
GUTS Fractyl Health	$0.98 +0.7%	$1.76	$0.83 ▼ $3.72	$48.19M	1.66	481,314 shs	1.45 million shs
KLRS Kalaris Therapeutics	$2.49 -6.4%	$2.66	$2.28 ▼ $24.15	$46.56M	0.49	40,907 shs	61,997 shs
OSTX OS Therapies	$1.78 +6.6%	$1.76	$1.12 ▼ $7.00	$50.01M	N/A	732,022 shs	309,323 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CANO Cano Health	0.00%	0.00%	0.00%	0.00%	0.00%
GUTS Fractyl Health	+1.62%	-47.47%	-35.72%	-44.80%	-45.11%
KLRS Kalaris Therapeutics	-0.37%	+3.10%	+9.47%	+265,999,900.00%	+265,999,900.00%
OSTX OS Therapies	-3.47%	-3.47%	-1.76%	-7.73%	-60.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CANO Cano Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	2.5192 of 5 stars	3.5	3.0	0.0	0.0	3.0	1.7	0.0
KLRS Kalaris Therapeutics	1.0517 of 5 stars	2.0	0.0	0.0	0.0	0.6	3.3	0.6
OSTX OS Therapies	2.4602 of 5 stars	3.7	0.0	0.0	0.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CANO Cano Health	0.00	N/A	N/A	N/A
GUTS Fractyl Health	3.00	Buy	$11.00	1,018.00% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	20.48% Upside
OSTX OS Therapies	3.40	Buy	$18.00	911.24% Upside

Current Analyst Ratings Breakdown

Latest CANO, GUTS, KLRS, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CANO Cano Health	$2.74B	0.00	N/A	0.03	$100.28 per share	0.00
GUTS Fractyl Health	$90K	535.46	N/A	N/A	$0.59 per share	1.67
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$22.47 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CANO Cano Health	-$207.27M	-$215.87	N/A	N/A	N/A	-18.62%	-133.59%	-19.18%	N/A
GUTS Fractyl Health	-$68.69M	-$1.85	N/A	N/A	N/A	-73,864.52%	-228.66%	-76.74%	8/12/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-62.08%	-54.69%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Latest CANO, GUTS, KLRS, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	GUTS Fractyl Health	-$0.37	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	GUTS Fractyl Health	-$0.49	-$0.49	N/A	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CANO Cano Health	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CANO Cano Health	3.95	0.40	0.40
GUTS Fractyl Health	4.61	2.50	2.50
KLRS Kalaris Therapeutics	N/A	14.31	14.31
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CANO Cano Health	35.99%
GUTS Fractyl Health	N/A
KLRS Kalaris Therapeutics	66.05%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
CANO Cano Health	13.93%
GUTS Fractyl Health	27.00%
KLRS Kalaris Therapeutics	74.99%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CANO Cano Health	4,365	5.41 million	4.65 million	Optionable
GUTS Fractyl Health	102	48.98 million	35.75 million	N/A
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

CANO, GUTS, KLRS, and OSTX Headlines

Recent News About These Companies

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

August 9 at 3:20 AM | finance.yahoo.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 7, 2025 | newsfilecorp.comN

OS Therapies files to sell 3.76M shares of common stock for holders

August 6, 2025 | msn.com

OS Therapies Inc News (OSTX) - Investing.com

July 18, 2025 | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

June 30, 2025 | businesswire.com

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24, 2025 | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025 | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

OSTX OS Therapies Incorporated

June 1, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANO, GUTS, KLRS, and OSTX Company Descriptions

Cano Health NYSE:CANO

Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.

Fractyl Health NASDAQ:GUTS

$0.98 +0.01 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.96 -0.03 (-2.63%)

As of 05:39 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Kalaris Therapeutics NASDAQ:KLRS

$2.49 -0.17 (-6.39%)

As of 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

OS Therapies NYSE:OSTX

$1.78 +0.11 (+6.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 -0.04 (-2.53%)

As of 05:40 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time